clusterin (CLU) is a secreted heterodimeric glycoprotein expressed in all organism fluids as well as in the intracellular matrix that plays key roles in several pathological processes. Its recent involvement in muscle degeneration of osteoporotic patients led to investigation of the role of CLU in bone metabolism, given the biochemical and biomechanical crosstalk of the bone-muscle unit. quantitative real time-polymerase chain reaction (qRT-PCR) analysis of CLU expression was performed in both osteoblasts and peripheral blood mononuclear cells (PBMCs) from osteoporotic patients (OP) and healthy individuals (CTR). furthermore, immunohistochemical analysis on femoral head tissues and enzyme-linked immunosorbent assay (ELISA) in plasma samples were performed to investigate CLU expression pattern. finally, genotyping of CLU rs11136000 polymorphism has also been performed by qRT-PCR assays to explore a possible association with CLU expression levels. data obtained showed a significantly increased expression level of secreted CLU isoform in PBMCs and osteoblasts from OP patients. Immunohistochemical analysis confirms the increased expression of CLU in OP patients, both in osteocytes and osteoblasts, while plasma analysis reveals a statistically significant decrease of CLU levels. unfortunately, no functional association between CLU expression levels and the presence of CLU rs11136000 polymorphism in OP patients was found. these data suggest a potential role played by CLU as a potential biomarker for the diagnosis and prognosis of OP progression.

Visconti, V.v., Greggi, C., Cariati, I., Gasperini, B., Mastrogregori, A., Botta, A., et al. (2022). Deregulated Clusterin as a Marker of Bone Fragility: New Insights into the Pathophysiology of Osteoporosis. GENES, 13(4), 652 [10.3390/genes13040652].

Deregulated Clusterin as a Marker of Bone Fragility: New Insights into the Pathophysiology of Osteoporosis

Greggi, Chiara;Cariati, Ida;Botta, Annalisa;Tarantino, Umberto
2022-04-07

Abstract

clusterin (CLU) is a secreted heterodimeric glycoprotein expressed in all organism fluids as well as in the intracellular matrix that plays key roles in several pathological processes. Its recent involvement in muscle degeneration of osteoporotic patients led to investigation of the role of CLU in bone metabolism, given the biochemical and biomechanical crosstalk of the bone-muscle unit. quantitative real time-polymerase chain reaction (qRT-PCR) analysis of CLU expression was performed in both osteoblasts and peripheral blood mononuclear cells (PBMCs) from osteoporotic patients (OP) and healthy individuals (CTR). furthermore, immunohistochemical analysis on femoral head tissues and enzyme-linked immunosorbent assay (ELISA) in plasma samples were performed to investigate CLU expression pattern. finally, genotyping of CLU rs11136000 polymorphism has also been performed by qRT-PCR assays to explore a possible association with CLU expression levels. data obtained showed a significantly increased expression level of secreted CLU isoform in PBMCs and osteoblasts from OP patients. Immunohistochemical analysis confirms the increased expression of CLU in OP patients, both in osteocytes and osteoblasts, while plasma analysis reveals a statistically significant decrease of CLU levels. unfortunately, no functional association between CLU expression levels and the presence of CLU rs11136000 polymorphism in OP patients was found. these data suggest a potential role played by CLU as a potential biomarker for the diagnosis and prognosis of OP progression.
7-apr-2022
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/03 - GENETICA MEDICA
Settore M-EDF/01
Settore MEDF-01/A - Metodi e didattiche delle attività motorie
English
biomarker
bone tissue
clusterin
osteoblasts
osteoporosis
Biomarkers
Humans
Leukocytes, Mononuclear
Real-Time Polymerase Chain Reaction
Clusterin
Osteoporosis
Visconti, V.v., Greggi, C., Cariati, I., Gasperini, B., Mastrogregori, A., Botta, A., et al. (2022). Deregulated Clusterin as a Marker of Bone Fragility: New Insights into the Pathophysiology of Osteoporosis. GENES, 13(4), 652 [10.3390/genes13040652].
Visconti, Vv; Greggi, C; Cariati, I; Gasperini, B; Mastrogregori, A; Botta, A; Tarantino, U
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Visconti et al_Genes (2022).pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 1.3 MB
Formato Adobe PDF
1.3 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/306239
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 3
social impact